Randomized drug trials not so randomized

In this meta study, only about one third of IBD patients reviewed would have been eligible to participate in FDA studies on the efficacy of biological agents (Adalimumab, Certolizumab pegol, Infliximab, Natalizumab, etc.) for IBD.

Most patients with moderate–severe IBD evaluated in an outpatient practice would not qualify for enrollment in a pivotal RCT of biological reagents; this finding raises important questions about their therapeutic efficacy beyond the clinical trial populations.

Here’s your link.

0 Responses to “Randomized drug trials not so randomized”

  1. Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Enter your email address to follow this blog and receive notifications of new posts by email. Your address will not be shared with any other parties.

What I'm Eating

%d bloggers like this: